



## Body Vision Medical Announces Successful Validation of LungVision™ System with Fujifilm's Range of Surgical C-arms

---

**CAMPBELL, Calif., March 5, 2024**– Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today the successful validation of Body Vision's LungVision™ system with FUJIFILM Healthcare Americas Corporation's [Persona line](#) of C-arms and [FDR Cross](#) two-in-one fluoroscopy C-arm and portable digital radiography solution.

Body Vision Medical's LungVision™ system uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans. This empowers bronchoscopists to biopsy from smaller, more difficult-to-access lung lesions at an earlier stage, thus maximizing the likelihood of an early diagnosis for lung cancer patients and improving odds for survival.

"This validation further demonstrates the power of an AI-driven imaging platform like LungVision™ that enables physicians to agnostically leverage our image-guided navigation and real-time imaging with the bronchoscopy platform and C-arm of their choice," said David Webster, CEO of Body Vision Medical. "Fujifilm's C-arms demonstrate very innovative and competitive thinking and pairing them with LungVision™ helps to create a complete image-guided navigational bronchoscopy solution for targeting the most challenging lesions."

"Fujifilm is committed to delivering innovative, best-of-breed solutions focused on enhancing patient experience while streamlining the procedural workflow for healthcare providers," said Rob Fabrizio, Director of Strategic Marketing for Diagnostic Imaging, FUJIFILM Healthcare Americas Corporation. "We're elated to see the successful validation of our C-arm platforms with Body Vision's leading LungVision™ system to synergistically provide the visualization needed by bronchoscopists during navigation bronchoscopy".

In May 2023, Body Vision Medical's LungVision™ solution was selected as the winner of the "Best New Biopsy Solution" award in the 7th Annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market. In April 2023, Fujifilm's FDR Cross C-arm fluoroscopy system received the "Best of the Best Award" by Red Dot Design Award program, a competitive, international design award program launched in 1955. The FDR Cross features revolutionary industry firsts including cord-free, 8-hour battery operation, antibacterial coating, 84cm opening, on-demand user removable detector, interchangeable detector sizes

and pivoting tube head to accommodate tabletop, cross table, standing, wheelchair exams and more.

### About Body Vision Medical

Body Vision Medical specializes in AI-driven, intraoperative imaging with the aim of saving lives through the democratization of innovative medical technology. Its first commercial product, LungVision™, addresses the unmet clinical need for early, definitive lung cancer diagnosis and, in the future, to enable effective treatment of lung lesions via a minimally-invasive procedure.

Visit [bodyvisionmedical.com](https://bodyvisionmedical.com) to learn more and connect with us on [LinkedIn](#).

### About Fujifilm

FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis and treatment of diseases. Fujifilm's innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The award-winning Synapse® Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm's AI initiative, REILI®, combines Fujifilm's rich image-processing heritage with cutting-edge innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labelling products. The company is headquartered in Lexington, Massachusetts. [Click here for more information.](#)

FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver "Value from Innovation" in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm's Sustainable Value Plan 2030, [click here](#). For the year ended March 31, 2023, the company had global revenues of approximately 2.9 trillion yen (21 billion USD at an exchange rate of 134 yen/dollar). For more information, please visit: [www.fujifilmholdings.com](https://www.fujifilmholdings.com).

